Table 1. Virological characteristics and YMDD patterns of patients on lamivudine treatment.
| Patient ID | Age/sex | Genotype |
Before lamivudine treatment
|
After lamivudine treatment
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HBV load* | No. of clones | No. of unique clones | YMDD mutation (%) | HBV load* | No. clones | No. unique clones | YMDD mutation (%) | |||
| 1 | 44/M | A/G† | — | — | — | — | 10.2 | 40 | 25‡ | M204I (65%), M204 V (35%) |
| 2 | 53/M | D | — | — | — | — | 8.8 | 45 | 25 | M204I (100%) |
| 3 | 54/F | C | — | — | — | — | 7.9 | 44 | 27 | M204I (98%), M204 V (2%) |
| 4 | 54/M | B | — | — | — | — | 9.2 | 41 | 34 | M204I (100%) |
| 5 | 64/F | C | — | — | — | — | 6.4 | 12 | 7 | M204I (100%) |
| 6 | 8/M | A | 9.3 | 41 | 29 | M204I (2%) | 7.9 | 45 | 21 | M204 V (100%) |
| 7 | 59/M | A | 12.8 | 36 | 29 | No | 9.9 | 34 | 19 | M204 V (100%) |
| 8 | 37/M | D | 8.9 | 41 | 36 | No | 8.9 | 40 | 19 | M204 V (98%) |
| 9 | 38/M | A/G¶ | 11.6 | 36 | 35 | M204I (3%) | 9.5 | 31 | 20 | None |
| 10 | 44/M | A | 9.2 | 44 | 43 | No | 10.5 | 35 | 35 | M204 V (74%), M204I (23%) |
| 11 |
57/M |
A |
12.3 |
46 |
46 |
No |
10.9 |
28 |
26 |
M204 V (100%) |
Abbreviations: F, female; M, male.
*log10 IU ml−1.
†Mixed HBV genotypes A and G.
‡A total of 25 clones were sequenced, among which 15 belonged to HBV genotype A and 10 to HBV genotype G.
¶Clones belonged to genotype G and recombinant genotype A/G before treatment and to recombinant genotype A/G after treatment.